Titan Pharmaceuticals (NASDAQ:TTNP) signed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding patient access to its Probuphine implant for the maintenance treatment of opioid use disorder (OUD) in eligible patients.
In February 2019, Titan inked a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime.
Titan’s strategic expansion of its network to include Accredo, one of the largest U.S. specialty pharmacies, is a key component of its focused commercialization strategy for Probuphine.
Titan expects the majority of Probuphine sales in the U.S. to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients’ insurance billing and payment processes, and ships to the healthcare provider as prescribed.
“Accredo is among the top specialty pharmacy networks in the U.S., with excellent relationships with third-party payers that should enhance the ability of OUD patients to gain access to long-term maintenance treatment with Probuphine,” Dane Hallberg, chief commercial officer of Titan, said in a statement.
Express Script’s Advanced Opioid Management program received the Pharmacy Benefit Management Institute’s excellence award in the opioid management strategy category in March 2018.
